Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: Observation based on a single-center experience

Transplant International

Volumn 23, Issue 6, 2010, Pages 580-588

  Tamura, Sumihito ^a   Sugawara, Yasuhiko ^a   Yamashiki, Noriyo ^b   Kaneko, Junichi ^a   Kokudo, Norihiro ^a   Makuuchi, Masatoshi ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

Hepatitis C; Interferon; Liver transplantation; Living donor; Pre emptive; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; CYCLOSPORIN; METHYLPREDNISOLONE; PEGINTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERFERON; RIBAVIRIN; STEROID; TACROLIMUS; VIRUS RNA; ALPHA INTERFERON; ALPHA2B INTERFERON; RECOMBINANT PROTEIN;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BLOOD SALVAGE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; LIVING DONOR LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; VIRUS LOAD; ADOLESCENT; BLOOD; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL;

EID: 77951944714     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.01023.x     Document Type: Article

References (51)

1. Poynard T, Bedossa P, Opolon I. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997 349 : 825. (Pubitemid 27129209)
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001 345 : 41.
3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006 144 : 705. (Pubitemid 46780630)
4. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004 127 : S17. (Pubitemid 39423366)
5. Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transplant 2006 6 : 449.
6. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006 355 : 2444.
7. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006 55 : 1350. (Pubitemid 44277369)
8. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006 130 : 231.
9. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006 130 : 225.
10. Berenguer M, Lopez-LabradBor FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001 35 : 666. (Pubitemid 33078280)
11. Powers KA, Ribeiro RM, Patel K, et al. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006 12 : 207. (Pubitemid 43273778)
12. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002 35 : 680. (Pubitemid 34183974)
13. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000 32 : 673. (Pubitemid 30180389)
14. Yilmaz N, Shiffman ML, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007 13 : 975. (Pubitemid 47163189)
15. Kalambokis G, Manousou P, Samonakis D, et al. Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl Int 2009 22 : 172.
16. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002 122 : 889.
17. Thuluvath PJ, Krok KL, Segev DL, Yoo HY. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl 2007 13 : 719.
18. Mutimer DJ, Gunson B, Chen J, et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation 2006 81 : 7. (Pubitemid 43122140)
19. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008 21 : 459. (Pubitemid 351490169)
20. Schmitt TM, Kumer SC, Pruett TL, Argo CK, Northup PG. Advanced recipient age (>60 years) alone should not be a contraindication to liver retransplantation. Transpl Int 2009 22 : 601.
21. Samuel D, Forns X, Berenguer M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006 45 : 127. (Pubitemid 43850627)
22. Carrión JA, Navasa M, García-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007 132 : 1746. (Pubitemid 46695723)
23. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006 6 : 1586. (Pubitemid 43945798)
24. Troppmann C, Rossaro L, Perez RV, McVicar JP. Early, rapidly progressive cholestatic hepatitis C reinfection and graft loss after adult living donor liver transplantation. Am J Transplant 2003 3 : 239. (Pubitemid 36323124)
25. Ghobrial RM, Amersi F, Douglas GF, et al. Rapid and early HCV recurrence following adult living donor liver transplantation. Am J Transplant 2002 2 : 163.
26. Schiano TD, Gutierrez JA, Walewski JL, et al. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 2005 42 : 1420.
27. Garcia-Retortillo M, Forns X, Llovet JM, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004 40 : 699. (Pubitemid 39265593)
28. Russo MW, Galanko J, Beavers K, Fried MW, Shrestha R. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004 10 : 340. (Pubitemid 38380305)
29. Van Vlierberghe H, Troisi R, Colle I, Ricciardi S, Praet M, de Hemptinne B. Hepatitis C infection-related liver disease: patterns of recurrence and outcome in cadaveric and living-donor liver transplantation in adults. Transplantation 2004 77 : 210. (Pubitemid 38155748)
30. Sugawara Y, Makuuchi M. Should living donor liver transplantation be offered to patients with hepatitis C virus cirrhosis? J Hepatol 2005 42 : 472. (Pubitemid 41427743)
31. Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001 33 : 1355. (Pubitemid 32237879)
32. Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005 5 : 118. (Pubitemid 40095135)
33. Wiesner RH, Sorrell M, Villamil F. Report of the first international liver transplant society consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003 9 : S1. (Pubitemid 37407996)
34. Sugawara Y, Makuuchi M. Living donor liver transplantation for patients with hepatitis C virus cirrhosis: Tokyo experience. Clin Gastroenterol Hepatol 2005 3 : S122. (Pubitemid 41427743)
35. Takada Y, Haga H, Ito T, et al. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients. Transplantation 2006 81 : 350. (Pubitemid 43255718)
36. Sugawara Y, Makuuchi M, Sano K, et al. Vein reconstruction in modified right liver graft for living donor liver transplantation. Ann Surg 2003 237 : 180. (Pubitemid 36460662)
37. Kokudo N, Sugawara Y, Imamura H, Sano K, Makuuchi M. Tailoring the type of donor hepatectomy for adult living donor liver transplantation. Am J Transplant 2005 5 : 1694. (Pubitemid 41427743)
38. Tamura S, Sugawara Y, Kokudo N. Donor evaluation and hepatectomy for living-donor liver transplantation. J Hepatobiliary Pancreat Surg 2008 15 : 79. (Pubitemid 351267275)
39. Yamashiki N, Sugawara Y, Tamura S, et al. Selection of liver-transplant candidates for adult-to-adult living donor liver transplantation as the only surgical option for end-stage liver disease. Liver Transpl 2006 12 : 1077. (Pubitemid 44063781)
40. Kishi Y, Sugawara Y, Akamatsu N, et al. Splenectomy and preemptive interferon therapy for hepatitis C patients after living-donor liver transplantation. Clin Transplant 2005 19 : 769. (Pubitemid 41748730)
41. Gedaly R, Clifford TM, McHugh PP, Jeon H, Johnston TD, Ranjan D. Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multi-center international survey. Transpl Int 2008 21 : 867.
42. Sugawara Y, Makuuchi M, Kaneko J, Ohkubo T, Imamura H, Kawarasaki H. Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation. Clin Transplant 2002 16 : 102. (Pubitemid 34414057)
43. Tamura S, Sugawara Y, Kishi Y, et al. Conversion to cyclosporine provides valuable rescue therapy for living donor adult liver transplant patients intolerant to tacrolimus: a single-center experience at the University of Tokyo. Transplant Proc 2004 36 : 3242. (Pubitemid 41126784)
44. Tamura S, Sugawara Y, Matsui Y, et al. Thrombotic microangiopathy in living-donor liver transplantation. Transplantation 2005 80 : 169. (Pubitemid 41061672)
45. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005 42 : 962. (Pubitemid 41401136)
46. Sugawara Y, Makuuchi M, Matsui Y, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004 78 : 1308. (Pubitemid 38283103)
47. Akuta N, Suzuki F, Kawamura Y, et al. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy. J Med Virol 2008 80 : 1363. (Pubitemid 351897407)
48. Kudo M, Sakaguchi Y, Chung H, et al. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology 2007 72 : 132. (Pubitemid 350256677)
49. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006 44 : 1543. (Pubitemid 44970357)
50. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008 359 : 2429.
51. Kuo A, Tan V, Lan B, et al. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl 2008 14 : 1491.